Lin Mengting, Li Yuqing, Long Haiyue, Lin Yueling, Zhang Zhuo, Zhan Fengyun, Li Manmei, Wu Chaoxi, Liu Zhong
Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, Department of Cellular Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, People's Republic of China.
Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, Department of Cellular Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, People's Republic of China.
Int J Biol Macromol. 2023 Jan 15;225:873-885. doi: 10.1016/j.ijbiomac.2022.11.152. Epub 2022 Nov 17.
Biomimetics plays an important role in cancer treatment since it can prolong the circulation of nanoparticles, enhance their delivery and retention in target tissues, and reduce the systemic toxicity of drugs and their carriers. In this study, we developed a biomimetic nanosystem consisting of chemotherapeutic and immunotherapeutic agents wrapped in cell membranes. Specifically, the anti-tumor drug doxorubicin (DOX) was loaded into a bacterial-derived immunomodulatory agent (low molecular weight curdlan, lCUR), and the lCUR-DOX was further wrapped in the red blood cell membrane for camouflage and prolonged circulation. The successful preparation of the lCUR-DOX@RBC nanosystem was supported by various optical and morphological characterizations. In vitro studies indicated that the nanosystem can escape uptake by macrophages, inhibit the invasion of tumor cells, and reprogram M2 macrophages with an immunosuppressive phenotype into M1 macrophages with an immunopromoting phenotype via the MAPK signaling pathway while promoting the phagocytosis of macrophages. In vivo studies showed that the nanosystem effectively inhibits tumor growth in the A-375 tumor-bearing mouse model. Taken together, the above results support further development of the lCUR-DOX@RBC platform for cancer immunochemotherapy in clinical applications.
仿生学在癌症治疗中发挥着重要作用,因为它可以延长纳米颗粒的循环时间,增强其在靶组织中的递送和滞留,并降低药物及其载体的全身毒性。在本研究中,我们开发了一种由包裹在细胞膜中的化疗和免疫治疗药物组成的仿生纳米系统。具体而言,将抗肿瘤药物阿霉素(DOX)负载到一种细菌衍生的免疫调节剂(低分子量的凝胶多糖,lCUR)中,然后将lCUR-DOX进一步包裹在红细胞膜中以实现伪装和延长循环时间。各种光学和形态学表征证实了lCUR-DOX@RBC纳米系统的成功制备。体外研究表明,该纳米系统能够逃避巨噬细胞的摄取,抑制肿瘤细胞的侵袭,并通过MAPK信号通路将具有免疫抑制表型的M2巨噬细胞重编程为具有免疫促进表型的M1巨噬细胞,同时促进巨噬细胞的吞噬作用。体内研究表明,该纳米系统在荷A-375肿瘤小鼠模型中能有效抑制肿瘤生长。综上所述,上述结果支持进一步开发lCUR-DOX@RBC平台用于临床癌症免疫化疗。